Israeli man facing early-onset Alzheimer's develops potential treatment for Parkinson's disease
Initially turned away, Ofer Shina built X-tosis around Prof. Varda Shoshan-Barmatz's research. The startup has a $2.74 million Michael J. Fox Foundation grant and is initially targeting Parkinson's.
Ofer Shina, a 38-year-old Israeli man with a gene that triggers early-onset Alzheimer's disease, has developed a potential treatment for Parkinson's disease. After his father and an uncle both suffered from Alzheimer's, Shina studied the genetic mutation PSEN1 in his family history. As a tech industry product manager with no background in biology, he taught himself to read scientific papers and searched for treatments in the literature.
After reviewing over 200 potential approaches and thousands of papers, he found the research of Prof. Varda Shoshan-Barmatz at Ben-Gurion University of the Negev. Shoshan-Barmatz studies a protein called VDAC1, which controls the flow of molecules in and out of mitochondria. Her lab developed a drug candidate, VBIT-4, which X-tosis, Inc. plans to use in trials.
The Michael J. Fox Foundation awarded X-tosis a $2.74 million grant to advance the drug toward human trials. Shoshan-Barmatz's research suggests that VDAC1 overproduction leads to cell death and inflammation, which may be triggered by the protein amyloid, the target of most Alzheimer's drugs.
Written by urgent.news from Jerusalem Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Type-2 diabetes may raise Alzheimer’s risk by 53%, study finds freemalaysiatoday.com
- New biomarkers for Alzheimer's disease, depression and beyond medicalxpress.com